Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 5/20 | 0.74 |
| ▸ | PYGM | P11217 | 3/20 | 0.66 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27786493 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13597474 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13447935 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13413052 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1532596 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23083301 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13252708 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2587226 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1532595 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7571099 | 1.00 | TK2 (0.74) | TK2PYGMSLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | claimed |
| US-6015573-A | TREATMENT OF RESISTANT HERPES VIRUS WITH NUCLEOSIDE PHOSPHATE ESTERS | RESOLUTION PERFORMANCE PRODUCTS LLC | 2000-01-18 | — | — | US | claimed |
| US-5879700-A | TREATING HERPES VIRUS INFECTIONS | HOSTETLER KARL Y (US) | 1999-03-09 | — | — | US | claimed |
| EP-0746319-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0746319-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| WO-2024124178-A1 | METHODS AND APPARATUS FOR TRANSFORM TRAINING AND CODING | Beijing Dajia Internet Information Technology Co., Ltd. (CN) | 2024-06-13 | — | — | WO | disclosed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| CN-105188693-A | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS LLC | 2015-12-23 | — | — | CN | disclosed |
| EP-0746319-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0746319-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5580571-A | ACYCLOIR MONO OR DIPHOSPHATE; TOPICAL USE IN HERPES VIRUSINFECTIONS | HOSTETLER KARL Y (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | disclosed |
| US-4542210-A | VIRICIDES, HERPES | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1985-09-17 | — | — | US | disclosed |
| EP-0074101-A1 | 1-Beta-D-arabinofuranosyl-(E)-5-(2-halogenovinyl) uracil-5'-phosphate, preparation thereof and use thereof | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | TK2 109/4885PYGM 579/4885SLC28A1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.